기사

(Photo = Prodizen)

According to BioTimes, Prodizen, a regenerative medicine company specializing in blood-based therapeutic platforms, participated in the 52nd Spring International Conference of the Korean Society for Laser, Dermatology and Hair (KALDAT), held on May 3 at COEX in Seoul, where it introduced clinical application strategies and future directions for blood-based regenerative medicine platforms.

Marking its 52nd edition this year, the conference was held under the theme “Therapeutic Strategy for Aesthetic Medicine” at Hall C on the 3rd floor of COEX. The event covered the latest clinical trends across various fields including dermatologic lasers, botulinum toxin, fillers, lifting procedures, obesity treatment, and hair restoration. Live discussions and real-time procedural sessions were also conducted, attracting a large number of medical professionals and industry experts. Recognized as one of Korea’s leading academic conferences in energy-based aesthetic and dermatologic medicine, KALDAT welcomed approximately 5,035 participants this year.

Prodizen, together with its partner medical institution O& Clinic, hosted a joint session focused on the clinical applications of blood-based regenerative platforms. During the C Room session, Dr. Myungjun Oh delivered a lecture titled:

“Clinical Evolution of Blood-Based Regenerative Platforms: Personalized Signal Therapies for Skin Restoration.”

The presentation introduced Prodizen’s GFC+ (Growth Factor Concentrate) platform, a regenerative solution developed based on the principles of conventional PRP technology, designed to selectively isolate and concentrate growth factors for enhanced regenerative applications. The session highlighted its potential across various skin regeneration and recovery-focused treatments.

Particular attention was drawn to real clinical application cases and regenerative medicine-based treatment protocols supported by clinical data. Discussions also explored personalized therapeutic strategies utilizing regenerative signaling tailored to individual skin conditions and treatment objectives.

A representative from Prodizen stated, “This conference provided a meaningful opportunity to share with medical professionals how regenerative medicine technologies are being applied in real-world aesthetic practice,” adding, “We will continue expanding clinical collaborations with partner medical institutions while broadening the applications of blood-based regenerative medicine platforms.”

Meanwhile, Prodizen has continued to develop regenerative medicine technologies since the early commercialization stage of PRP in Korea and is expanding its presence in both domestic and global medical markets through its GMP-based manufacturing infrastructure and blood-based regenerative platform technologies.

Source: BioTimes